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Abstract
Background: Disparate and contradictory results make studies necessary to investigate in more depth the relationship
between diagnostic delay and survival in colorectal cancer (CRC) patients. The aim of this study is to analyse the
relationship between the interval from first symptom to diagnosis (SDI) and survival in CRC.
Methods: Retrospective study of n = 942 CRC patients. SDI was calculated as the time from the diagnosis of
cancer and the first symptoms of CRC.
Cox regression was used to estimate five-year mortality hazard ratios as a function of SDI, adjusting for age and
gender. SDI was modelled according to SDI quartiles and as a continuous variable using penalized splines.
Results: Median SDI was 3.4 months. SDI was not associated with stage at diagnosis (Stage I = 3.6 months, Stage
II-III = 3.4, Stage IV = 3.2; p = 0.728). Shorter SDIs corresponded to patients with abdominal pain (2.8 months), and
longer SDIs to patients with muchorrhage (5.2 months) and rectal tenesmus (4.4 months).
Adjusting for age and gender, in rectum cancers, patients within the first SDI quartile had lower survival (p = 0.
003), while in colon cancer no significant differences were found (p = 0.282). These results do not change after
adjusting for TNM stage.
The splines regression analysis revealed that, for rectum cancer, 5-year mortality progressively increases for SDIs
lower than the median (3.7 months) and decreases as the delay increases until approximately 8 months. In colon
cancer, no significant relationship was found between SDI and survival.
Conclusions: Short diagnostic intervals are significantly associated with higher mortality in rectal but not in
colon cancers, even though a borderline significant effect is also observed in colon cancer. Longer diagnostic
intervals seemed not to be associated with poorer survival. Other factors than diagnostic delay should be taken
into account to explain this “waiting-time paradox”.
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Background
Colorectal cancer (CRC) is one of the leading causes of
deaths due to cancer worldwide. It is the third most com-
mon cancer in men (10.0 % of the total) and the second in
women (9.2 % of the total), affecting mainly to developed
regions [1]. In Europe, CRC is the most common cancer
and the second most common cancer causing death, with
an estimated number of 436,000 new cases and 212,000
deaths in 2008 [2].
In Spain, age-adjusted incidence rates went from 20.4
cases per 100,000 population in the period 1975–1979
to 45.9 in the period 2000–2004 [3]. Mortality registered
at a much lower increase than incidence with a turning
point in 1997–1998 and a subsequent decline in rates,
reaching an age-adjusted mortality rate of 20.5 per
100,000 in 2003–2007 [3]. The same trend was observed
in other European countries, with an increase in inci-
dence and a decrease in mortality, probably associated
with an improvement in CRC survival [4, 5].
Despite evidence clearly suggesting that CRC screen-
ing reduces CRC incidence and mortality [6], implemen-
tation of colorectal cancer screening in Spain is limited
[7]. As a result, most patients with CRC are diagnosed
after the onset of clinical symptoms, and only few cases
are diagnosed at an asymptomatic stage as a result of
screening programs.
Although symptoms vary with tumour location, typical
symptoms associated with CRC include rectorrhagia, hema-
tochezia or melena, changes in bowel habits, abdominal
pain, loss of weight, iron deficiency anaemia, and intestinal
obstruction [8]. Once the symptoms are presented, it is un-
clear the role of diagnostic and therapeutic delay in the
prognosis of these patients. Intuitively, longer diagnostic
delays (defined as the time between the first symptoms and
the diagnosis of CRC) or therapeutic delays (defined as the
time between first symptoms and initiation of treatment)
might be associated with a poor prognosis. However, in
regard to CRC, contradictory results have been obtained:
whereas most studies have not found a significant associ-
ation between delay and survival [9–14], other authors have
reported, as expected, a poorer prognosis for patients with
greater delays [15, 16]. Counterintuitive results have even
been published, showing that patients with shorter diagnos-
tic intervals had higher mortality rates [15, 17], leading to
what is called the “waiting-time paradox”.
Two recent systematic reviews and meta-analysis have
not found association between delay and CRC stage at
diagnosis, nor between delay and survival [18, 19]. How-
ever, their results are not conclusive and should be
interpreted taken into account the heterogeneity among
the included studies, in terms of inclusion/exclusion
criteria, delay definition, and the manner of measuring
it. In some studies, opposite findings seem to be found
in colon and rectum tumours, suggesting that future
research should assess colon and rectum cancers
separately.
Most of the studies have assumed a monotonic linear
association between the symptom-to-diagnosis interval
(SDI) and mortality [20]. To the extent that this assump-
tion is not fulfilled, such an analysis could lead to wrong
conclusions. Other authors have tested the theory of a
U-shaped association between diagnostic delay and mor-
tality in CRC patients [21–23]. Their results support the
theory that longer diagnostic intervals cause higher mor-
tality in patients with CRC. However, a higher mortality
was also found in patients with very short diagnostic inter-
vals, probably due to confounding by indication. Failure to
consider this nonlinear effect may explain previous non-
significant findings reported by other researchers.
In conclusion, disparate and contradictory results
make studies necessary to investigate in more depth the
relationship between diagnostic delay and survival in
CRC. It is especially important to check the consistency
of published results with that obtained from different
CRC cohorts in other countries, and with different
healthcare systems. Additionally, non-linear association
of diagnostic delay with mortality should be investi-
gated. The aim of this study was to determine the rela-
tionship of diagnostic delay with survival in a cohort of
Spanish CRC patients.
Methods
Observational retrospective cohort study of incident
cases of CRC diagnosed at the Complexo Hospitalario
Universitario A Coruña (A Coruña, northwest Spain) dur-
ing 1994–2000. This is a 1382-beds public tertiary care
hospital attending a population of nearly 560.000 habitants.
The study population included all incident cases with
anatomopathological confirmation of CRC according
to the International Classification of Diseases (ICD) 9th
revision (codes 153 and 154) during the study period
(N = 1482).
This study finally included N = 942 patients with avail-
able data from clinical records to calculate SDI. This
sample size makes it possible to detect as significant, in
a Cox regression model, a relative risk of 1.3 or more as-
sociated with greater delay, assuming an exposure to
this possibility of 50 % and a censored data percentage
of 50 % (Security: 95 %; Statistical power: 80 %). In
terms of the censoring value, we have estimated a 50 %
censorship as according to published data [24] the esti-
mated survival rate at 5 years for colorectal cancer in
Spain is 61.2 %. In this situation, the sample size required
to estimate a relative risk of 1.3 or more (α = 0.05, ß = 0.2)
would be N = 912 patients.
Clinical records were reviewed retrospectively in
order to collect data regarding patients’ age, gender,
symptoms and signs before diagnosis, symptoms-to-
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diagnosis interval, location of neoplasm and TNM stage
at diagnosis. Diagnosis delay or symptoms-to-diagnosis
interval (SDI) was defined as the time elapsed from the
date the patient perceived the first symptoms attribut-
able to CRC until the anatomopathological confirm-
ation of the diagnosis of cancer (date of biopsy or
direct surgery). Since a patient could present more than
one symptom/sign attributable to CCR before being di-
agnosed, the date of the earliest symptom was selected
in order to calculate SDI.
Patients were followed for at least 5 years after the
diagnosis, until death or censoring. Thereby, the study
outcome was 5-year mortality after diagnosis. Informa-
tion on death was retrieved from the Galician Mortality
Registry.
Statistical analysis
Descriptive analysis was performed for all variables stud-
ied. Continuous variables were reported using means ±
standard deviations (SD) or median (interquartile range).
For dichotomous/categorical variables, absolute numbers
and percentages were computed.
SDI was analysed according to patients’ demographic
characteristics, tumour location and stage using the
Mann-Whitney and Kruskall-Wallis test. After categoriz-
ing SDI into quartiles, multivariate logistic regression
analysis was performed to determine its association with
the tumour stage at diagnosis, adjusting for age and gen-
der as potential confounders.
Survival was estimated by the Kaplan-Meier method,
and homogeneity of curves was assessed using the log-
rank test. Influence of SDI on survival was determined
in two ways. First, Kaplan-Meier survival curves were
computed for each SDI interval quartile, and compared
using the log-rank test. Second, SDI was treated as a
continuous variable using restricted cubic splines with
four knots and using the 50th percentile (3.4 months) as
reference point [25]. This approach allow for a flexible
association between the length of the diagnostic interval
and mortality, without assuming a linear association. In
both cases, the estimated 5-year hazard ratios were esti-
mated as a function of the length of the delay interval
and adjusted for age and gender, using proportional haz-
ard Cox regression.
IBM-SPSS software, release 19 (IBM, Armonk, NY,
USA) and R software v3.2.1 (The R Foundation for Stat-
istical Computing) were used for statistical analysis. Bi-
lateral P-values <0.05 were considered as statistically
significant.
Results
After inspection of clinical records, data on SDI was
available in N = 942 (63.6 %) incident cases of colorectal
cancer. Patients with missing data on diagnosis delay
were similar in age (68.8 ± 11.6 vs. 68.0 ± 11.4; P = 0.251)
and gender (58.5 % vs. 53.3 % men; P = 0.051) to those
with accessible information.
The N = 942 patients with data on SDI were included
in the analysis. The main characteristics of these pa-
tients were summarized in Table 1, together with the
symptoms and signs evidenced before diagnosis. Mean
age was 68.0 (±11.4) years, with 53.3 % being men.
Most of the patients had stage II (35.0 %) or stage III
(31.7 %) disease, whereas 20.1 % had metastatic stage
IV colorectal cancer. Rectal bleeding was the most
common symptom in tumours located in the rectum
(87.0 %) and the third in colon tumours (47.1 %), be-
hind abdominal pain (60.6 %) and changes in bowel
habits (49.5 %).
Median SDI was 3.4 months, significantly higher in rec-
tum than colon tumours (3.7 vs. 3.2 months; P < 0.001).
No significant differences were found in diagnosis delay
according with gender (3.2 vs. 3.7 months; P = 0.051) or
age (P = 0.100), although higher delays were found in
younger patients (Table 2). Also, SDI was not found to
be significantly associated with stage at diagnosis (Stage
I: 3.6 months, Stage II-III: 3.4 months, Stage IV: 3.2
months; P = 0.728), even after adjusting for age and
gender (Table 3). The same results are obtained after
taking into account the diagnosis period. The symptom
associated with a shorter SDI was abdominal pain (2.8
months). On the contrary, those symptoms associated
with a longer delay were muchorrhage (5.2 months), rectal
tenesmus (4.4 months) and rectal bleeding (4.0months)
(Table 2).
Overall, survival probability at 1 year was 85.9 %, at 3
years 65.1 % and at 5 years 50.5 %. No differences were
found in survival between rectum and colon tumours,
with a 5-year survival probability of 47.3 and 51.9 %, re-
spectively (P = 0.379).
For rectal cancer patients, those with shorter delays
(in the 1st quartile group of SDI) showed a significantly
poorer prognosis than patients with higher delays.
Therefore, survival probability at 5 years was 30.9 % for
rectal cancer patients in the 1st quartile group, compared
with 46.5, 55.5 and 55.0 % (P = 0.001) for patients in the
2nd, 3th and 4rd quartile groups, respectively. On the
other hand, for colon cancer patients, a progressive in-
crease in 5-year survival was also found with SDI
quartiles. Five-year survival probability increased from
47.8 % for the 1st quartile group to 59.0 % in the 4rd
quartile group, but without reaching statistical signifi-
cance (P = 0.163) (Fig. 1, Table 4).
Results in the univariate analysis were confirmed after
adjusting for age and gender in a multiple Cox regression
model (Table 5, Model 1). Thus, a significant effect of SDI
on survival was found in rectum tumours (P = 0.003) but
not in colon tumours (P = 0.282). Results were similar
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even after adjusting for stage at diagnosis, showing that
more advanced stages and lower delays are associated with
a worse prognosis (Table 5, Model 2). Those results are
also confirmed after taken into account the diagnosis
period.
Furthermore, in rectal cancer patients, the cubic
splines regression analysis also revealed that the 5-years
adjusted risk of death decreased significantly with higher
delays until approximately 7–8 months (Fig. 2a). In con-
trast, for colon cancer patients, no significant association
was found between SDI and 5-year mortality (Fig. 2b).
Discussion
This study examined diagnostic delay as the time from first
CRC symptoms until diagnosis and assessed its association
with overall mortality. A median diagnosis delay of 3.4
months was found, slightly higher in rectum than in colon
tumours. Results also showed that short diagnostic intervals
are significantly associated with higher mortality in rectal
cancer, but not in colon cancer, even though a borderline
significant effect is also observed in colon cancer. Further-
more, longer diagnostic intervals seemed not to be associ-
ated with poorer survival in colorectal cancer patients.
Table 1 Features and symptoms/signs of incident cases of colorectal cancer, according with tumor’s location
Total
N = 942
Colon
N = 650
Rectum
N = 292
Mean ± SD Median Mean ± SD Median Mean ± SD Median P
Age, years 68.0 ± 11.4 69 68.0 ± 11.5 69 68.1 ± 11.0 68 0.922
N %
Gender 0.236
Male 502 53.3 % 338 52.0 % 164 56.2 %
Female 440 46.7 % 312 48.0 % 128 43.8 %
Stage <0.001
I 113 13.2 % 60 10.0 % 53 20.9 %
II 300 35.0 % 226 37.5 % 74 29.1 %
III 271 31.7 % 194 32.2 % 77 30.3 %
IV 172 20.1 % 122 20.3 % 50 19.7 %
Unknown 86 - 48 - 38 -
Symptoms/signs before diagnosisa
Rectal bleeding 560 59.4 % 306 47.1 % 254 87.0 % <0.001
Change in bowel habits 489 51.9 % 321 49.5 % 168 57.5 % 0.022
Abdominal pain 454 48.2 % 393 60.6 % 61 20.9 % <0.001
Constitutional syndrome 454 48.2 %
Rectal tenesmus 163 17.3 % 59 9.1 % 104 35.6 % <0.001
Anemia 126 13.4 % 107 16.5 % 19 6.5 % <0.001
Bowel obstruction 124 13.2 % 115 17.7 % 9 3.1 % <0.001
Abdominal mass 57 6.1 % 51 7.9 % 6 2.1 % 0.001
Mucorrhage 48 5.1 % 30 4.6 % 18 6.2 % 0.320
Rectal pain 38 4.0 % 7 1.1 % 31 10.6 % <0.001
Bowel perforation 29 3.1 % 26 4.0 % 3 1.0 % 0.014
Intra-abdominal abscess 16 1.7 % 14 2.2 % 2 0.7 % 0.106
Rectovaginal fistula 4 0.4 % 3 0.5 % 1 0.3 % 0.999
Hematuria 3 0.3 % 3 0.5 % 0 0 % 0.556
Fecal urgency 2 0.2 % 1 0.3 % 1 0.2 % 0.525
Fecal incontinence 2 0.2 % 1 0.3 % 1 0.2 % 0.525
Anal fistula 2 0.2 % 1 0.3 % 1 0.2 % 0.525
Fecaluria 1 0.1 % 1 0.2 % 0 0 % 0.999
SD Standard Deviation
aMore than one symptom or sign could be registered before diagnosis for the same patient
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Symptoms-to-diagnosis interval
Diagnostic delay in this study was significantly lower in
comparison with other reported series in Spain [26, 27],
being closer to the results found in a recent multicenter
study made in 5 Spanish regions which reported a median
delay of 4.2 months [28]. Shorter diagnosis delays were re-
ported in studies in other countries [13, 15, 16, 22, 23].
Significantly longer SDI was found in rectal (3.7 months)
than in colon (3.2 months) tumours, similarly to that re-
ported by other authors [16, 17], although in other series a
longer delay was found in colon cancers [15]. Never-
theless, comparison of delay estimates across studies is
difficult because of the different definitions of delay, inclu-
sion criteria, patients’ characteristics and disparities in
models of health care delivery.
Symptoms-to-diagnosis interval and stage at diagnosis
Results obtained also confirmed the lack of significant
association between SDI and disease stage at diagnosis,
which had already been reported in a recent systematic
review [19]. Although most of the studies included in
that review showed no significant association between
delay and disease stage, a great variability was found
among them, with contradictory results continuing to be
published now. Therefore, while several studies find no
association between diagnosis delay and stage at diagno-
sis [14, 16, 27], others continue to report longer delays
in tumours diagnosed with earlier stages [13, 15, 17].
Although without achieving statistical signification this
was also the general trend observed with our data, with
median delay varying from 3.6 months for stage I to 3.2
months for stage IV tumours. However, when colon and
rectal cancers were analysed separately, and after adjust-
ing for age and gender, this trend was only observed for
cancers in the rectum. The opposite was reported in the
previously mentioned review [19], where a shorter delay
was associated with less advanced disease in rectal can-
cers, while in the case of colon cancers a longer delay
was associated with less advanced disease. The same
Table 2 Symptoms-to-diagnosis interval, according to different
variables
Symptoms-to-diagnosis interval (months)
Mean ± SD Median Interquartilic range
Total 5.3 ± 6.0 3.4 1.5–6.4
Age
< 50 6.6 ± 8.5 4.1 2.0–7.9
50–60 5.2 ± 5.1 3.4 1.9–6.5
60–70 5.4 ± 5.9 3.5 1.8–6.7
70–80 5.4 ± 6.3 3.2 1.6–6.3
> 80 4.5 ± 5.1 2.7 1.1–5.4
Gender
Men 5.0 ± 5.8 3.2 1.4–6.3
Women 5.6 ± 6.2 3.7 1.8–6.6
Tumor location
Colon 5.0 ± 6.0 3.2 1.3–6.2
Rectum 5.9 ± 6.0 3.7 2.2–7.3
Stage
I 5.7 ± 6.5 3.6 2–6.2
II 5.2 ± 5.6 3.4 1.4–6.7
III 5.3 ± 6.3 3.4 1.4–6.4
IV 5.0 ± 5.5 3.2 1.8–6.1
Symptoms before diagnosisa
Abdominal pain 4.6 ± 5.7 2.8 1.1–6.1
Constitutional syndrome 5.5 ± 5.8 3.5 2.2–6.3
Abdominal mass 5.4 ± 5.4 3.5 2.1–6.7
Change in bowel habits 5.6 ± 6.0 3.7 2.1–6.7
Anemia 6.0 ± 5.8 3.9 2.3–7.2
Rectal pain 6.2 ± 6.4 3.9 2.1–8.7
Rectal bleeding 6.1 ± 6.4 4.0 2.1–7.4
Rectal tenesmus 6.0 ± 6.0 4.4 2.2–7.5
Mucorrhage 8.0 ± 7.6 5.2 3.0–12.0
SD Standard Deviation
aIn order to compute the symptoms-to-diagnosis interval, the earliest symptom
was selected for each patient
Table 3 Logistic regression analysis of risk of stage III/IV at diagnosis in relation to symptom-to-diagnosis interval, adjusting for age
and gender
Total Colon Rectum
P OR 95 % CI P OR 95 % CI P OR 95 % CI
Age 0.113 0.99 0.98–1.00 0.045 0.99 0.97–1.00 0.841 1.00 0.98–1.03
Gender (female) 0.412 0.89 0.68–1.70 0.253 0.83 0.60–1.14 0.833 1.06 0.63–1.77
SDI quartile 0.873 0.798 0.267
1st quartile 1 1 1
2nd quartile 0.614 1.11 0.73–1.70 0.352 1.25 0.78–2.02 0.205 0.48 0.15–1.50
3rd quartile 0.839 0.96 0.62–1.46 0.523 1.17 0.72–1.90 0.068 0.35 0.11–1.08
4rd quartile 0.947 1.01 0.67–1.54 0.396 1.23 0.76–1.97 0.085 0.37 0.12–1.15
OR Odds Ratio, CI Confidence Interval, SDI Symptoms-to-Diagnosis Interval
Pita-Fernández et al. BMC Cancer  (2016) 16:664 Page 5 of 11
finding was reported by Jullumstrø et al. [17] for colon
tumours.
Therefore, although results published seems to con-
firm that no association exists between delay and disease
stage at diagnosis, so controversy persists. Our work
overcomes some of the limitations pointed out by Ramos
et al. [19] for this kind of study, since it includes a large
sample of incident CRC patients, using the TNM staging
scheme, which is the preferred classification. However,
due to the retrospective design, we could not have taken
into account the potential effect or other variables such
as the comorbidity or the degree of tumour differenti-
ation, that were not available from clinical records and
could act as confounders in this context.
Symptoms-to-diagnosis interval and mortality
Similarly, results on the relationship between diagnostic
delay and survival are not conclusive. Although the re-
sults of a recent meta-analysis suggest that longer delay
in CRC is related to improved survival, this is by no
Fig. 1 Estimated survival for each symptom-to-diagnosis interval quartile for colon and rectum incident cases
Pita-Fernández et al. BMC Cancer  (2016) 16:664 Page 6 of 11
means certain [18]. Most of the published studies
include restricted samples with variable definitions of
diagnosis delay. Furthermore, there were well-known
prognostic factors that were not accounted for. This lim-
itations warrant further studies to clarify the role of
diagnostic delay on survival of CRC patients.
Most of the published studies do not find an associ-
ation between delay and survival [13, 14, 29] or they re-
port higher survival rates in patients with longer delays
[16, 17]. Since epidemiological, etiological and genetic
factors suggest that colorectal cancer is not a single
entity, recent studies have analysed colon and rectal tu-
mours separately, both describing different results. For
example, Jullumstrø et al. [17] showed how increasing
SDI was associated with better survival in colon cancer,
but not in rectal cancer. Similar results were reported in
the work by Pruitt et al. [15], where colon cancer pa-
tients with the longest diagnosis delays had higher all-
cause mortality, whereas in rectal cancer patients delay
was not associated with survival.
Comparison among studies is difficult, not only due to
differences in their design, but also in the way data was
analysed. Many studies use different cut-off points to ex-
plore the influence of SDI on survival, considering an
arbitrary cut-off or the median value to classify patients
with “short” or “long” delays. Other studies represent
SDI as a continuous, monotonic variable in a standard
Cox proportional survival analysis [30]. However, as
some authors have pointed out, SDI could have different,
non-linear association with mortality risk [20]. Ignoring
this possibility could lead to not detecting the true na-
ture of the relationship between SDI and survival.
One of the main strengths of this study is that it allows
for a continuous, non-monotonic effect of delay in
mortality risk. Following this idea, several works have re-
ported a U-shaped association between diagnostic inter-
val and mortality in CRC [21–23]. In a prospective,
population-based study in Denmark, Tørring et al. found
how the risk of dying decreased with diagnostic intervals
up to 5 weeks and then increased in patients with symp-
toms suggestive of cancer or any other serious illness,
whereas this association was reverse (although not sta-
tistically significant) in patients presenting vague symp-
toms [21]. Analogous results were found in a more
recent study [22]. The same authors analysed three
population-based CRC studies in Denmark and the UK
using different methods to collect information on diag-
nostic delay, confirming the U-shaped association with
decreasing and subsequently increasing mortality with
longer diagnostic intervals [22]. More recently, the same
results were replicated in another cohort of colorectal
cancer, as well as in patients with lung, melanoma skin,
breast and prostate tumours. For all of them, very short
or long diagnostic intervals were associated with in-
creased mortality in those patients arising with alarm
symptoms suggestive of cancer. On the contrary, no
Table 4 Estimated survival for each symptoms-to-diagnosis interval quartile for colorectal cancer incident cases
Survival probability
6 months 1 year 2 years 3 years 4 years 5 years
Total
1st quartile (<1.5 months) 85.6 % 81.2 % 73.7 % 61.3 % 50.4 % 45.6 %
2nd quartile (1.5–3.4 months) 90.6 % 84.1 % 71.7 % 62.9 % 52.3 % 44.2 %
3rd quartile (3.4–6.4 months) 92.6 % 88.4 % 77.5 % 65.7 % 59.0 % 55.0 %
4rd quartile (>6.4 months) 92.1 % 87.7 % 78.6 % 68.6 % 63.9 % 54.5 %
Log-rank = 9.263; P = 0.026
Colon
1st quartile (<1.3 months) 86.7 % 82.7 % 75.1 % 67.2 % 54.3 % 47.8 %
2nd quartile (1.3–3.2 months) 88.6 % 82.7 % 70.7 % 64.3 % 54.9 % 47.6 %
3rd quartile (3.2–6.2 months) 92.7 % 87.7 % 76.2 % 63.4 % 55.7 % 53.1 %
4rd quartile (>6.2 months) 90.5 % 85.8 % 79.0 % 70.8 % 68.0 % 59.0 %
Log-rank = 5.120; P =0.163
Rectum
1st quartile (<2.2 months) 87.0 % 78.2 % 61.3 % 40.7 % 34.2 % 30.9 %
2nd quartile (2.2–3.7 months) 95.9 % 91.6 % 79.5 % 67.1 % 56.1 % 46.5 %
3rd quartile (3.7–7.3 months) 95.8 % 88.6 % 82.7 % 66.2 % 63.2 % 55.5 %
4rd quartile (>7.3 months) 94.5 % 94.5 % 80.2 % 74.3 % 66.9 % 55.0 %
Log-rank = 16.963; P =0.001
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statistically significant association was found between
the length of the diagnostic interval and mortality in pa-
tients presenting with vague symptoms [23].
Our results confirm these findings only partially, with
very short diagnostic intervals being associated with
higher mortality in rectal tumours, while longer diagnos-
tic intervals were not associated to a lower survival in
rectal or colon cancers. This paradox, of shorter diag-
nostic intervals associated with lower survival, has been
explained by the effect of unmeasured confounder fac-
tors (such as phenotype, biological virulence or tumour
aggressiveness). So, rapidly growing tumours are be-
lieved to present more alarming symptoms, being associ-
ated to shorter delays and, on the other hand, to a worse
survival. Other authors have argued these findings as a
result of confounding by indication [21–23]. In any case,
the conclusion is similar: patients with short and long
SDIs are inherently different, and probably there are
other factors than diagnostic delay that modify the prog-
nosis of these patients.
On the other hand, we must keep in mind that the
symptomatic period of an illness is only a little portion
of the total natural history of a neoplastic disease. The
asymptomatic period plays an important role, as it has
been demonstrated with the efficacy of screening of
CRC in asymptomatic patients to reduce mortality [6].
Limitations
Limitations of the present study could include selection
bias, information bias and residual confounding.
Perhaps the main limitation of this study is its retro-
spective design, which makes it vulnerable to information
bias from inaccurate clinical records and missing data. We
can add this to the difficult of measuring time intervals in
the diagnostic pathway. Prospective studies will ideally be
performed in order to measure the SDI more accurately.
Furthermore, patients may remember different symptoms,
that can be directly or indirectly related to the disease,
and therefore differently being interpreted as first symp-
tom. Nevertheless, in three population-based studies of
incident CRC patients analogous results have been found,
even when different methods of identifying the date of
first presentation were used [22].
Although a large cohort of all incidents CRC cases were
studied, data on SDI was unavailable in 36.4 % of those
patients. There were not differences between patients with
Table 5 Cox regression model to determine the effect of each symptom-to-diagnosis interval quartile on survival, adjusting for
a) age, gender and b) age, gender and stage at diagnosis
Total Colon Rectum
P HR 95 % CI P HR 95 % CI P HR 95 % CI
a) Model 1
Age <0.001 1.02 1.01–1.03 <0.001 1.01 1.01–1.03 0.007 1.02 1.01–1.04
Gender (female) 0.029 0.81 0.67–0.98 0.009 0.73 0.58–0.92 0.872 1.03 0.73–1.45
SDI quartile 0.079 0.282 0.003
1st quartile 1 1 1
2nd quartile 0.979 1.00 0.75–1.34 0.798 1.04 0.76–1.43 0.022 0.59 0.38–0.93
3rd quartile 0.089 0.77 0.57–1.04 0.600 0.92 0.67–1.26 0.004 0.50 0.31–0.80
4rd quartile 0.104 0.78 0.59–1.05 0.115 0.76 0.54–1.07 0.001 0.46 0.29–0.74
b) Model 2
Age <0.001 1.02 1.01–1.03 0.001 1.02 1.01–1.03 0.003 1.03 1.01–1.05
Gender (female) 0.143 0.86 0.70–1.05 0.109 0.85 0.63–1.05 0.835 0.96 0.66–1.40
SDI quartile 0.115 0.160 0.084
1st quartile 1 1 1
2nd quartile 0.855 0.97 0.71–1.32 0.854 0.97 0.69–1.36 0.534 0.85 0.52–1.40
3rd quartile 0.088 0.76 0.55–1.04 0.176 0.79 0.56–1.11 0.003 0.56 0.34–0.94
4rd quartile 0.100 0.77 0.56–1.05 0.052 0.70 0.49–1.01 0.006 0.58 0.33–1.02
TNM stage at diagnosis <0.001 <0.001 <0.001
I 1 1 1
II 0.002 2.07 1.29–3.33 0.083 1.72 0.93–3.18 0.003 3.23 1.51–6.92
III <0.001 3.17 1.99–5.05 0.002 2.57 1.40–4.72 <0.001 4.94 2.38–10.24
IV <0.001 12.40 7.56–19.81 <0.001 10.10 5.47–18.61 <0.001 19.07 9.05–40.15
HR Hazard Ratio, CI Confidence Interval, SDI Symptoms-to-Diagnosis Interval
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available data and patients without this information re-
garding age and gender. For that reason we assume that
missing data are independent both of observable variables
and of unobservable parameters of interest and occurred
entirely at random, although the existence of some selec-
tion bias could not be totally discarded. Even though there
are other time intervals that could be studied, like the
symptoms-to-treatment interval (the time interval from
first symptom to start of treatment), the health service
interval (the time interval from the first contact with
health service to diagnosis), or the treatment interval
(time interval from the diagnosis to start of treatment), we
focused on the SDI in order to check the consistency of
our results with different meta-analysis [18, 19].
Other studies have only included patients whose diagno-
sis general practitioners were involved, obtaining more
homogeneous groups and increasing therefore internal
validity. In this study, we included all the incident cases di-
agnosed during the study period independently from the
access to the healthcare system, increasing the external
validity. Residual confounding could also be present, since
there could be additional confounding factors, such as
tumour aggressiveness, histological type or comorbidity
which were not available in the analysis.
In the same sense, controversy exists about whether or
not to adjust by tumour stage when the relationship be-
tween diagnostic delay and survival is examined. Some
authors argue that stage at diagnosis is a mediator or
intermediate factor between delay and survival, since it
is in the pathway between both variables (longer delays
cause more advanced diseases, and more advanced
stages are associated with poorer survival) [21]. If it is
Fig. 2 Nonparametric estimates of the dependence of overall survival on symptoms-to-diagnosis interval (restricted to the interval between 0
and 24 months) among patients with colorectal cancer (log 5-years hazard ratio, with 95 % confidence limits). Reference value = median
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the case, adjusting for tumour stage would introduce
spurious confounding. However if we adjust for stage at
diagnosis, results do not change.
Conclusions
Despite these limitations this is a large-sample study in-
vestigating the relationship between diagnostic delay and
disease stage and survival in CRC patients. After CRC
symptoms, diagnosis delay seems not to affect survival
of patients with tumours located in the colon. For rec-
tum cancers survival was worse for those patients with
lower SDIs. The results suggest that, contrary to what
might be expected, greater diagnostic delay is not neces-
sarily associated with a worse prognosis. However, we
must not forget that long delays could be associated with
other adverse events, like postoperative complications,
hospital stay, quality of life or other psychosocial out-
comes such as anxiety.
The different results found in the literature can prob-
ably also be explained by the methodological differences
among the studies and the differences in healthcare
systems. Further prospective multicenter studies, in-
volving large cohorts of patients with all confounding
factors should be designed to get more information
about this issue.
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